

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of the Claims:**

Claims 1-13 (cancelled)

Claim 14 (new): A single unit dosage form comprising greater than about 25 mg of an active ingredient and an excipient, wherein:

the active ingredient is thalidomide or a pharmaceutically acceptable prodrug, salt, solvate, or clathrate thereof;

the active ingredient constitutes from about 30 to about 50 weight percent of the dosage form; and

the single unit dosage form is a size #0 capsule, a size #1 capsule, a size #2 capsule, a size #4 capsule, or a size #5 capsule.

Claim 15 (new): The dosage form of claim 14, wherein the active ingredient constitutes about 40 percent by weight of the dosage form and the dosage form is a size #0 capsule, a size #1 capsule, a size #2 capsule, or a size #4 capsule.

Claim 16 (new): The dosage form of claim 15, which is a size #0 capsule.

Claim 17 (new): The dosage form of claim 15, which is a size #1 capsule.

Claim 18 (new): The dosage form of claim 15, which is a size #2 capsule.

Claim 19 (new): The dosage form of claim 15, which is a size #4 capsule.

Claim 20 (new): The dosage form of claim 14, which comprises from about 50 mg to about 200 mg active ingredient.

Claim 21 (new): A single unit dosage form comprising about 200 mg of an active ingredient and one or more excipients, wherein:

the active ingredient is thalidomide or a pharmaceutically acceptable prodrug, salt, solvate, or clathrate thereof; and

the dosage form is a size #0 capsule.

Claim 22 (new): The dosage form of claim 21, wherein the one or more excipients comprises pregelatinized starch and/or magnesium stearate.

Claim 23 (new): The dosage form of claim 21, wherein the active ingredient constitutes about 40 percent weight percent of the dosage form.